EGFR and head and neck squamous cell carcinoma: As a whole, the data presented in our study not only align with those of prior studies informing of the enhanced activity and potentially increased efficacy of cetuximab-based treatments post-ICI but may also lead to a new issue, which is the role of sequential treatments, including ICI- and anti-EGFR rechallenge, and may open the possibility for individualized sequential treatment strategies in patients with R/M SCCHN (26).